share_log

Corcept Completes Enrollment In Pivotal Phase 3 Rosella Trial Of Relacorilant In Patients With Platinum-Resistant Ovarian Cancer

Corcept Completes Enrollment In Pivotal Phase 3 Rosella Trial Of Relacorilant In Patients With Platinum-Resistant Ovarian Cancer

Corcept完成了針對鉑耐藥卵巢癌患者的Relacorilant的關鍵性3期Rosela試驗的入組
Benzinga ·  04/08 20:05

Corcept Completes Enrollment In Pivotal Phase 3 Rosella Trial Of Relacorilant In Patients With Platinum-Resistant Ovarian Cancer

Corcept完成了針對鉑耐藥卵巢癌患者的Relacorilant的關鍵性3期Rosela試驗的入組

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論